What if..., page-27

There is some scientific literature on CBD and atopic dermatitis, nonetheless what BOT is doing is groundbreaking stuff (and the market hasn't fully realized it yet).

Here's a page from a paper titled Itch in atopic dermatitis - pathophysiology and treatment  .....and it bodes quite well for the incoming results:





....."These preliminary data suggest that topically applied cannabinoid agonists may have a role in future models of antipruritic therapy"...


Let's remember that scientific research is driven by financial interests and contingent on the allocation of funds. This paper is 8 years old, why the scientific thread wasn't followed up is anyone guess.
For BOT's holders this negligence highlights the risks but  may well turn up to be a blessing in disguise cause -IF the data is good- it'll put BTX1204 at the cutting edge of therapeutic solutions and on the radar of big-pharma.

​